Diagnostic X-rays and risk of epithelial ovarian carcinoma in Jews

Annals of Epidemiology

Volumn 12, Issue 6, 2002, Pages 426-434

  Harlap, Susan ^a   Olson, Sara H ^b   Barakat, Richard R ^b   Caputo, Thomas A ^c   Forment, Silvia ^a   Jacobs, Allan J ^a   Nakraseive, Christine ^d   Xue, Xiaonan ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Department of Obstetrics Gynecology   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

BRCA1 2; Case Control Studies; Diagnostic Radiation; DNA Repair; Ethnic Groups; Genetic Susceptibility; Host Factors; Jews; Ovary Neoplasms; Translational Research

Indexed keywords

ADULT; ARTICLE; BARIUM ENEMA; CASE CONTROL STUDY; DNA REPAIR; ETHNIC DIFFERENCE; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; JEW; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; RNA TRANSLATION; UNITED STATES; X RAY;

ADULT; AGED; CARCINOMA; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JEWS; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; NEW YORK CITY; ODDS RATIO; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 0036328682     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1047-2797(01)00301-5     Document Type: Article

References (60)

1. Relation of benzodiazepine use to the risk of selected cancers; breast, large bowel, malignant melanoma, lung, endometrium, ovary, non- Hodgkin's lymphoma, testis, Hodgkin's disease, thyroid, and liver
2. Psychotropic medication use and risk of epithelial ovarian cancer
3. Increased risk for familial ovarian cancer among Jewish women; a population-based case-control study
4. Cancer in United States Jews
5. Ethnic-related incidence of ovarian carcinoma in New York City
6. Contraceptive patterns of religious and racial groups in the United States, 1955-1976; convergence and distinctiveness
7. Patterns of American Jewish fertility
8. Patterns of contraceptive use in the United States; the importance of religious factors
9. Epidemiologic analysis of breast and gynecologic cancers
10. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women
11. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel; frequency and differential penetrance in ovarian cancer and in breast- ovarian cancer families
12. High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history
13. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer
14. Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls
15. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer
16. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients
17. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer
18. Frequency of germline and somatic BRCA1 mutations in ovarian cancer
19. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews
20. Insights into the functions of BRCA1 and BRCA2
21. DNA double-strand breaks; signaling, repair and the cancer connection
22. Lessons learned from BRCA1 and BRCA2
23. Ataxia-telangiectasia; founder effect among north African Jews
24. Carrier testing for seven diseases common in the Ashkenazi Jewish population; implications for counseling and testing
25. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers
26. Association of the I1307K APC mutation with hereditary and sporadic breast/ovarian cancer; more questions than answers
27. Neoplasms in persons treated with x-rays in infancy; fourth survey in 20 years
28. Thyroid cancer among persons given X-ray treatment in infancy for an enlarged thymus gland
29. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer
30. Handheld cellular telephone use and risk of brain cancer
31. Selection of controls using a commercial database and random digit dialing
32. Epithelial ovarian carcinoma and European birthplace of grandparents
33. Symptoms of ovarian cancer
34. The multi-step nature of carcinogenesis and the implications for risk analysis
35. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks
36. Genetic variability in susceptibility and response to toxicants
37. Polymorphisms in the DNA repair gene XRCC1 and breast cancer
38. Benign thyroid tumors; general risk factors and their effects on radiation risk estimation
39. Ionizing radiation and cancer risk; evidence from epidemiology
40. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer
41. Personal characteristics relating to risk of invasive epithelial ovarian cancer in older women in the United States
42. Cancer incidence in atomic bomb survivors. Part II; Solid tumors, 1958-1987
43. Malignant and benign ovarian neoplasms among atomic bomb survivors, Hiroshima and Nagasaki, 1950-80
44. Studies of the mortality of A-bomb survivors. 8. Cancer mortality, 1950-1982
45. Studies of the mortality of A-bomb survivors. 9. Mortality, 1950- 1985; Part 1. Comparison of risk coefficients for site-specific cancer mortality based on the DS86 and T65DR shielded kerma and organ doses
46. Leukemia and other malignancies following radiation therapy for gynecologic disorders
47. Cancer mortality following radium treatment for uterine bleeding
48. Late effects of x irradiation in patients treated for metropathia haemorrhagica
49. Cancer risk following radiotherapy for infertility or menstrual disorders
50. Long term follow-up of patients with menorrhagia treated by irradiation
51. Radiation dose and second cancer risk in patients treated for cancer of the cervix
52. Radiation dose and breast cancer risk in patients treated for cancer of the cervix
53. Characteristics relating to ovarian cancer risk; collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group
54. Linking DNA damage and neurodegeneration
55. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy; implications for breast-conserving management in patients with BRCA1/BRCA2 mutations
56. The key and the lamppost
57. BRCA1/2 germline mutations; a marker for radioresistance or radiosensitivity?